• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Royal Philips

FDA approves Philips’ low-dose Stellarex balloons

October 15, 2019 By Sean Whooley

philips-logo

Royal Philips (NYSE:PHG) said today that two of the company’s new Stellarex drug-coated balloons received FDA approval for the treatment of upper leg artery blockages. The approval was for both de novo and restenotic lesions in upper leg arteries. The Amsterdam-based company said the new low-dose (200 mm and 150 mm) balloons will be added to […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: FDA, Royal Philips

Philips touts Stellarex balloon study

October 1, 2019 By Sean Whooley

philips-stellarex-low-dose-drug-coated-balloon

Royal Philips (NYSE:PHG) said today that third-party data from worldwide clinical trials for the Stellarex drug-coated balloon showed that there was no difference in mortality between patients treated with the device compared to uncoated percutaneous transluminal angioplasty. The primary analysis consisted of three-year patient-level data from the Illumenate pivotal trial and the Illumenate European randomized controlled […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured Tagged With: Royal Philips

FDA panel wants more, better data on paclitaxel-eluting devices

June 21, 2019 By Brad Perriello

FDA

An FDA advisory panel on paclitaxel-eluting devices for treating peripheral artery disease yesterday found that the mortality signal indicated by a meta-analysis last year exists but that further study is needed to determine whether it’s a class effect and to pin down the cause of death. A meta-analysis published in the Journal of the American Heart Assn. last December […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Stents, Vascular Tagged With: Becton Dickinson, Boston Scientific, cook medical, Medtronic, Peripheral Artery Disease, Royal Philips

Philips touts Stellarex drug-coated balloon data

May 30, 2019 By Danielle Kirsh

philips-stellarex-low-dose-drug-coated-balloon

Patients using Royal Philips’s (NYSE:PHG) Stellarex drug-coated balloon maintained blood flow through the treated segment of diseased arteries at three years in a pair of clinical trials. Stellarex is designed to restore and maintain blood flow in the superficial femoral artery and peripheral arteries. It’s coated using the company’s EnduraCoat technology to elute the drug paclitaxel. […]

Filed Under: Big Data, Clinical Trials, Vascular Tagged With: Royal Philips

Medtech stories we missed this week: June 8, 2018

June 8, 2018 By Danielle Kirsh

missed-medtech-0323

From Royal Philips receiving FDA clearance to NeuroPace launching its epilepsy treatment device, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. FDA clears Philips’s Ingenia Elition 3.0T MR scanner Royal Philips announced in a June 5 press releasethat it has received FDA 510(k) clearance for its Ingenia Elition […]

Filed Under: Featured, Food & Drug Administration (FDA), Hospital Care, Imaging, Implants, Neurological, Patient Monitoring, Regulatory/Compliance Tagged With: branchpointtechnologies, cook medical, medtech, NeuroPace, Pentax Medical, rodomedical, Royal Philips, spineology, taewoonmedical

These 10 medtech companies care a lot about research

November 29, 2017 By Chris Newmarker

Among the world’s largest medtech companies, these 10 spent the largest portion of their budgets on research and development. So what have they produced? Every year, Medical Design & Outsourcing pulls financial regulatory filings and reaches out to major, companies in some cases to create a list of the 100 largest medical device companies in […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Research & Development Tagged With: abiomed, Big 100, biomerieux, DexCom Inc., Insulet, Royal Philips, Spectranetics

ASTRO ’17 Round-up: Novocure touts five-year results for Optune, chemo combo in newly-diagnosed glioblastoma patients

September 25, 2017 By Sarah Faulkner

American Society for Radiation Oncology ASTRO annual meeting

Novocure (NSDQ:NVCR) touted data today from the Phase III pivotal trial of its Optune device in combination with temozolomide for the treatment of newly-diagnosed glioblastoma. The analyses were presented at the American Society for Radiation Oncology’s 2017 annual meeting in San Diego. The company’s EF-14 trial showed unprecedented five-year survival results in patients with newly-diagnosed GBM, […]

Pages: Page 1 Page 2 Page 3 Page 4 Page 5 Page 6

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: Mayo Clinic, NovoCure, Royal Philips, viewray

VIVA 17 Round-up: Medtronic touts real-world data for In.Pact Admiral drug-coated balloon

September 12, 2017 By Sarah Faulkner

Medtronic

Medtronic (NYSE:MDT) touted data for its In.Pact Admiral drug-coated balloon this week at the Vascular Interventional Advances (VIVA) 2017 conference. The company presented two-year, real-world data from the In.Pact Global study, as well as four-year results from the pivotal In.Pact SFA study. Data from the In.Pact Global study showed a 83.3% rate of freedom from clinically-driven target […]

Pages: Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Vascular Tagged With: acotecscientific, C.R. Bard, cook medical, Medtronic, Mercator MedSystems, Royal Philips, SurModics Inc.

Philips, Illumina to launch precision medicine cancer program with Navican

June 1, 2017 By Sarah Faulkner

Royal Philips (NYSE:PHG) and Intermountain Healthcare company Navican inked an agreement today to launch a precision health informatics solution aimed at improving outcomes for late stage cancer patients. The program is slated to leverage Navican‘s TheraMap Precision Cancer Care services and Philips’ IntelliSpace Genomics platform, which uses Illumina‘s next-gen genomic sequencing technologies. At Utah-based Intermountain Healthcare’s […]

Filed Under: Big Data, Clinical Trials, Featured, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: illumina, navican, Royal Philips

Philips sees image-guided therapy transforming healthcare: Here’s how

April 3, 2017 By Danielle Kirsh

Officials at medtech giant Royal Philips see image-guided therapy as key when it comes to health practitioners providing care that is both efficient and effective. The Dutch multinational’s work in the field provides a great example of how the ever-growing need for cost-effective healthcare around the world is driving the strategies of medical device companies. […]

Filed Under: Imaging, Surgical Tagged With: augmented reality, imaging, Philips, Royal Philips, value-based care, X-rays

  • Page 1
  • Page 2
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS